Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 21, 2021
Product Development

Synthetic lethality’s second wind

The thinking goes beyond the binary paradigm of target plus mutation
BioCentury | May 9, 2018
Distillery Therapeutics

Cancer

BioCentury | Mar 8, 2017
Distillery Therapeutics

Infectious disease

BioCentury | Dec 7, 2016
Clinical News

GNS identifies disease drivers from CoMMpass data

BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Lipopolysaccharide (LPS)

BioCentury | Sep 19, 2013
Distillery Therapeutics

Indication: Cancer

BioCentury | Oct 29, 2012
Clinical News

Dinaciclib: Phase IIb/III started

BioCentury | Aug 2, 2012
Distillery Therapeutics

Indication: Cancer

Items per page:
1 - 10 of 13